Study treatment
stroke, death
STROKE
Both groups received a standard dose of 0.9 mg/kg rtPA (alteplase) administered intravenously within 4.5 h after symptom onset (maximal dosage 90 mg, 10% of the drug given in bolus and the rest in 60 min via intravenous infusion). In addition, measures of standard care for AIS patients were applied for both groups. Patients in the Cerebrolysin group additionally received 30 mL of Cerebrolysin diluted in 100 mL of normal saline administered intravenously through a separate line over 20 min. Cerebrolysin treatment was initiated simultaneously with IVT and continued once daily for 14 consecutive days. Acceptable and prohibited co-medications are listed in Table List of Acceptable and Prohibited Co-Medications
• Baseline stroke therapy• Medications for compensation of electrolyte and acid–base abnormalities• Symptomatic medications (antihypertensive, antidiabetic agents, drugs to normalize sleep (excluding benzodiazepines), antibiotics, and antipyretics)
• Neuroprotective or nootropic agents (citicoline, memantine, amantadine, erythropoietin, diazepam, investigational neuroprotective drugs, piracetam, pramiracetam, pyritinol, meclosulfonate, glycine, etc.)• Medications with vasodilatory effect (naftidrofuryl, cinnarizine, flunarizine, nimodipine, nicergoline, pentoxifylline, ergoloid, vinpocetine, vincamine, ginkgo biloba, etc.)• Antioxidant agents (lipoic acid, ethylmethylhydroxypyridine succinate, etc.)• Levodopa and dopamine agonists• Statins within the first 7 days from the stroke onsetAll participants were treated in the hospital settings since inpatient length of stay was at least 14 days according to the national insurance standard for patients with AIS.Patients were withdrawn from further intervention in case neurosurgery was performed or a life-threatening medical (non-neurological) condition occurred. The patient’s participation was discontinued in case of death. The subjects had the opportunity to exit the study at any time.The intention-to-treat (ITT) population comprised all recruited patients, subjects completed the study were included in the per-protocol (PP) analysis. The study ended once the required number of patients was reached and the protocol was accomplished by the participants.